PTEN and neoplasm: The PFS median (the primary endpoint) was 5.9 months with capivasertib, and 4.2 with the placebo; in patients with PIK3CA/AKT/PTEN, the altered tumours PFS median was 9.3 months with capivasertib vs. 3.7 months with the placebo (HR 0.30).